MCID: ATY042
MIFTS: 53

Atypical Chronic Myeloid Leukemia

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Atypical Chronic Myeloid Leukemia

MalaCards integrated aliases for Atypical Chronic Myeloid Leukemia:

Name: Atypical Chronic Myeloid Leukemia 12 60 30 6 15
Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative 45 74
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative 12
Subacute Myeloid Leukemia 60
Atypical Cml 12
Acml 12

Characteristics:

Orphanet epidemiological data:

60
atypical chronic myeloid leukemia
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060597
MeSH 45 D054438
NCIt 51 C3176 C3519
ICD10 34 C92.2 C92.20
MESH via Orphanet 46 D054438
ICD10 via Orphanet 35 C92.2
UMLS via Orphanet 75 C0349640 C1292772
Orphanet 60 ORPHA98824
UMLS 74 C1292772

Summaries for Atypical Chronic Myeloid Leukemia

Disease Ontology : 12 A myelodysplastic myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.

MalaCards based summary : Atypical Chronic Myeloid Leukemia, also known as leukemia, myeloid, chronic, atypical, bcr-abl negative, is related to myelodysplastic myeloproliferative cancer and myeloid leukemia. An important gene associated with Atypical Chronic Myeloid Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways are ERK Signaling and Developmental Biology. The drugs Cytarabine and Mercaptopurine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Atypical chronic myeloid leukemia (aCML) is a type of leukemia. It is a heterogeneous disorder... more...

Related Diseases for Atypical Chronic Myeloid Leukemia

Diseases related to Atypical Chronic Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 myelodysplastic myeloproliferative cancer 31.0 ABL1 ASXL1 CSF3R JAK2 SETBP1
2 myeloid leukemia 31.0 ABL1 CSF3R JAK2
3 leukemia, chronic myeloid 30.1 ABL1 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
4 chronic neutrophilic leukemia 30.0 ASXL1 CSF3R SETBP1
5 chronic myelomonocytic leukemia 29.4 ASXL1 CSF3R JAK2 PDGFRB SETBP1
6 leukemia, acute myeloid 28.9 ABL1 ASXL1 CSF3R JAK2 SETBP1
7 myeloproliferative neoplasm 28.4 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
8 subacute myeloid leukemia 12.6
9 leukemia 10.8
10 pdgfrb-associated chronic eosinophilic leukemia 10.3
11 sm-ahnmd 10.2 ASXL1 PDGFRA
12 acute erythroid leukemia 10.1 JAK2 PCM1
13 hematopoietic stem cell transplantation 10.0
14 cellular neurofibroma 10.0 ABL1 PDGFRB
15 desmoid tumor 10.0 PDGFRA PDGFRB
16 hypereosinophilic syndrome, idiopathic 10.0 PDGFRA PDGFRB
17 splenomegaly 10.0 JAK2 SETBP1
18 heart sarcoma 10.0 PDGFRA PDGFRB
19 refractory anemia 10.0 ASXL1 JAK2
20 neutrophilia, hereditary 10.0 CSF3R JAK2
21 corneal dystrophy, subepithelial mucinous 10.0 PDGFRA PDGFRB
22 spinal chordoma 9.9 PDGFRA PDGFRB
23 chromosomal triplication 9.9
24 leukemia, chronic lymphocytic 2 9.9
25 leukemia, chronic lymphocytic 9.9
26 thyroid cancer, nonmedullary, 1 9.9
27 lymphocytic leukemia 9.9
28 pulmonary alveolar proteinosis 9.9
29 thyroid cancer 9.9
30 pneumonia 9.9
31 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.9
32 leukemia, b-cell, chronic 9.9
33 tetrasomy 21 9.9
34 fibrosarcoma of bone 9.9 PDGFRA PDGFRB
35 spondylocarpotarsal synostosis syndrome 9.9
36 primary polycythemia 9.8 ABL1 ASXL1 JAK2
37 essential thrombocythemia 9.8 ABL1 ASXL1 JAK2
38 gastrointestinal stromal tumor 9.8 ABL1 PDGFRA PDGFRB
39 8p11 myeloproliferative syndrome 9.7 FGFR1 PDGFRB
40 lymphoblastic leukemia, acute, with lymphomatous features 9.6 ABL1 FGFR1 JAK2
41 primary hypereosinophilic syndrome 9.6 FGFR1 PDGFRA PDGFRB
42 thrombocytopenia-absent radius syndrome 9.6 FGFR1 JAK2
43 chronic leukemia 9.6 ASXL1 CSF3R JAK2 SETBP1
44 juvenile myelomonocytic leukemia 9.6 JAK2 PDGFRA PDGFRB SETBP1
45 polycythemia vera 9.5 ABL1 JAK2 PDGFRA PDGFRB
46 chronic eosinophilic leukemia 9.4 ABL1 FGFR1 PDGFRA PDGFRB
47 hypereosinophilic syndrome 9.4 ABL1 FGFR1 PDGFRA PDGFRB
48 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 9.3 FGFR1 JAK2 PDGFRA PDGFRB
49 glioma 9.2 FGFR1 PDGFRA PDGFRB
50 systemic mastocytosis 9.1 ASXL1 FGFR1 JAK2 PDGFRA PDGFRB

Graphical network of the top 20 diseases related to Atypical Chronic Myeloid Leukemia:



Diseases related to Atypical Chronic Myeloid Leukemia

Symptoms & Phenotypes for Atypical Chronic Myeloid Leukemia

GenomeRNAi Phenotypes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

27 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.22 PDGFRA
2 Decreased viability GR00221-A-1 10.22 ABL1 PDGFRA PDGFRB FGFR1
3 Decreased viability GR00221-A-2 10.22 ABL1 FGFR1
4 Decreased viability GR00221-A-3 10.22 ABL1 PDGFRA PDGFRB
5 Decreased viability GR00221-A-4 10.22 PDGFRA PDGFRB
6 Decreased viability GR00342-S-1 10.22 ABL1 PDGFRB
7 Decreased viability GR00342-S-2 10.22 ABL1
8 Decreased viability GR00342-S-3 10.22 ABL1
9 Decreased viability GR00402-S-2 10.22 ABL1 PDGFRA PDGFRB FGFR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.72 CSF3R
11 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.72 SETBP1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.72 CSF3R
13 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.72 PDGFRA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.72 CSF3R
15 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.72 CSF3R PDGFRA SETBP1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.72 SETBP1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.72 CSF3R SETBP1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 CSF3R
19 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.72 SETBP1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.72 SETBP1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.72 SETBP1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.72 SETBP1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.72 CSF3R
24 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.72 PDGFRA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.72 PDGFRA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.72 PDGFRA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.72 CSF3R
28 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.72 PDGFRA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.72 SETBP1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.72 SETBP1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 SETBP1

MGI Mouse Phenotypes related to Atypical Chronic Myeloid Leukemia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.98 ABL1 ASXL1 CSF3R FGFR1 JAK2 PDGFRA
2 craniofacial MP:0005382 9.8 ABL1 ASXL1 FGFR1 PDGFRA PDGFRB
3 endocrine/exocrine gland MP:0005379 9.8 ABL1 ASXL1 FGFR1 JAK2 PDGFRA PDGFRB
4 hematopoietic system MP:0005397 9.8 ABL1 ASXL1 CSF3R FGFR1 JAK2 PDGFRA
5 digestive/alimentary MP:0005381 9.77 ABL1 ASXL1 FGFR1 PDGFRA PDGFRB
6 immune system MP:0005387 9.7 ABL1 ASXL1 CSF3R FGFR1 JAK2 PDGFRA
7 mortality/aging MP:0010768 9.56 ABL1 ASXL1 CSF3R FGFR1 JAK2 PDGFRA
8 skeleton MP:0005390 9.1 ABL1 ASXL1 FGFR1 JAK2 PDGFRA PDGFRB

Drugs & Therapeutics for Atypical Chronic Myeloid Leukemia

Drugs for Atypical Chronic Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 310)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1 147-94-4, 65-46-3 6253
2
Mercaptopurine Approved Phase 3 50-44-2 667490
3
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
4
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
5
Idarubicin Approved Phase 3 58957-92-9 42890
6
Lenograstim Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 135968-09-1
7
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
9
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
10
Decitabine Approved, Investigational Phase 3,Phase 1 2353-33-5 451668
11
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
12
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
13
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
14
Acyclovir Approved Phase 3 59277-89-3 2022
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Daunorubicin Approved Phase 3 20830-81-3 30323
17
Thioguanine Approved Phase 3 154-42-7 2723601
18
Mitoxantrone Approved, Investigational Phase 3,Phase 2 65271-80-9 4212
19
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
20
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 460612 4053
21
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
22
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
23
Norgestimate Approved, Investigational Phase 3,Not Applicable 35189-28-7 6540478
24
Ethinyl Estradiol Approved Phase 3,Not Applicable 57-63-6 5991
25
Polyestradiol phosphate Approved Phase 3,Not Applicable 28014-46-2
26
Estradiol Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-28-2 5757
27
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
28
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 444795 5538
29 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
32 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
33 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
36 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
37 Interferon-alpha Phase 3,Phase 2
38 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
40 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
41 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
45 interferons Phase 3,Phase 2
46 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
47 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Excitatory Amino Acids Phase 3
49 Anesthetics Phase 3
50 Anesthetics, Dissociative Phase 3

Interventional clinical trials:

(show top 50) (show all 204)
# Name Status NCT ID Phase Drugs
1 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
2 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00025402 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
5 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
6 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
7 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
8 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
9 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
15 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
16 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
17 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
18 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
19 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
20 Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Unknown status NCT00044954 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
21 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
22 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
23 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
24 Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia Completed NCT00079313 Phase 2 Imatinib
25 Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia Completed NCT00002598 Phase 2 cyclophosphamide;cytarabine;etoposide;methotrexate;mitoxantrone hydrochloride
26 Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders Completed NCT00002792 Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate;tacrolimus
27 Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed NCT00217386 Phase 2
28 Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma Completed NCT00002681 Phase 1, Phase 2
29 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
30 Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders Completed NCT02210858 Phase 1, Phase 2 Tipifarnib
31 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
32 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
33 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
34 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
35 Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed NCT00093366 Phase 1, Phase 2 arsenic trioxide
36 Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Completed NCT00052832 Phase 2
37 Cholecalciferol in Treating Patients With Myelodysplastic Syndrome Completed NCT00068276 Phase 2
38 Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder Completed NCT00274820 Phase 2 arsenic trioxide;dexamethasone;thalidomide
39 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
40 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
41 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
42 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
43 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
44 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
45 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
46 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
47 Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
48 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
49 High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors Completed NCT00060255 Phase 2 busulfan;carboplatin;carmustine;cyclophosphamide;etoposide;melphalan;thiotepa
50 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2

Search NIH Clinical Center for Atypical Chronic Myeloid Leukemia

Cochrane evidence based reviews: leukemia, myeloid, chronic, atypical, bcr-abl negative

Genetic Tests for Atypical Chronic Myeloid Leukemia

Genetic tests related to Atypical Chronic Myeloid Leukemia:

# Genetic test Affiliating Genes
1 Atypical Chronic Myeloid Leukemia 30

Anatomical Context for Atypical Chronic Myeloid Leukemia

MalaCards organs/tissues related to Atypical Chronic Myeloid Leukemia:

42
Myeloid, Bone, Bone Marrow, Neutrophil, Liver, Eye, Breast

Publications for Atypical Chronic Myeloid Leukemia

Articles related to Atypical Chronic Myeloid Leukemia:

(show top 50) (show all 66)
# Title Authors Year
1
Current and evolving understanding of atypical chronic myeloid leukemia. ( 30078497 )
2019
2
Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. ( 30635983 )
2019
3
Pulmonary alveolar proteinosis developing during steroid treatment in a patient with organizing pneumonia in association with atypical chronic myeloid leukemia. ( 30899476 )
2019
4
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL). ( 31102420 )
2019
5
Atypical chronic myeloid leukemia: a rare entity with management challenges. ( 29226717 )
2018
6
Sudden Intracranial Hemorrhage in a Patient With Atypical Chronic Myeloid Leukemia in Chronic Phase. ( 29227326 )
2018
7
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. ( 29455651 )
2018
8
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. ( 29468060 )
2018
9
A typical atypical chronic myeloid leukemia. ( 29744086 )
2018
10
Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. ( 30458320 )
2018
11
Leukemia cutis presenting as scaly plaques in a Christmas tree distribution in a patient with atypical chronic myeloid leukemia. ( 27853001 )
2017
12
How I treat atypical chronic myeloid leukemia. ( 27899359 )
2017
13
Atypical chronic myeloid leukemia in a German Shepherd Dog. ( 28205462 )
2017
14
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. ( 28314085 )
2017
15
Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report. ( 28927137 )
2017
16
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. ( 28983816 )
2017
17
Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq. ( 29025591 )
2017
18
Atypical Chronic Myeloid Leukemia in Two Pediatric Patients. ( 26274939 )
2016
19
Activity of single-agent decitabine in atypical chronic myeloid leukemia. ( 26378157 )
2016
20
Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases. ( 26870268 )
2016
21
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, in a 5-Month Baby - ARare Presentation. ( 28666496 )
2016
22
Erratum to: Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. ( 25821085 )
2015
23
Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature. ( 26017341 )
2015
24
A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia. ( 26185647 )
2015
25
Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia. ( 26870618 )
2015
26
Transformation from atypical chronic myeloid leukemia to chronic myelomonocytic leukemia as progression of myeloid neoplasm with platelet-derived growth factor ß rearrangement. ( 26881541 )
2015
27
Centromeric fragment of chromosome 7 in atypical chronic myeloid leukemia with the SET binding protein 1 gene mutation. ( 24991718 )
2015
28
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. ( 25343957 )
2015
29
Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. ( 25426665 )
2015
30
Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. ( 25491280 )
2015
31
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. ( 24627528 )
2014
32
Establishment and characterization of a rare atypical chronic myeloid leukemia cell line NT-1. ( 25012564 )
2014
33
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. ( 25180155 )
2014
34
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. ( 25239264 )
2014
35
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. ( 25498990 )
2014
36
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. ( 23222956 )
2013
37
Successful transplantation of ethnically mismatched cord blood in a boy with atypical chronic myeloid leukemia. ( 23264127 )
2013
38
A BCR-JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia. ( 23432689 )
2013
39
Atypical chronic myeloid leukemia harboring NUP98-HOXA9. ( 23754767 )
2013
40
Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene. ( 23904814 )
2013
41
Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia. ( 21707937 )
2012
42
Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. ( 22289493 )
2012
43
t(3;21)(q22;q22) leading to truncation of the RYK gene in atypical chronic myeloid leukemia. ( 19168282 )
2009
44
JAK2 mutation and atypical chronic myeloid leukemia. ( 19427035 )
2009
45
The role of peripheral blood, bone marrow aspirate and especially bone marrow trephine biopsy in distinguishing atypical chronic myeloid leukemia from chronic granulocytic leukemia and chronic myelomonocytic leukemia. ( 19500135 )
2009
46
Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. ( 18555525 )
2008
47
A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. ( 17764812 )
2007
48
Identification of risk factors in atypical chronic myeloid leukemia. ( 17043019 )
2006
49
A case of leukemic pleural infiltration in atypical chronic myeloid leukemia. ( 17043433 )
2006
50
A variant t(8;10;21) in a patient with pathological features mimicking atypical chronic myeloid leukemia. ( 15860363 )
2005

Variations for Atypical Chronic Myeloid Leukemia

ClinVar genetic disease variations for Atypical Chronic Myeloid Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 FLT3; MYO18A t(13;17)(q12.2;q11.2) Translocation Likely pathogenic GRCh37 Chromosome 13, 28608270: 28608271
2 FLT3; MYO18A t(13;17)(q12.2;q11.2) Translocation Likely pathogenic GRCh37 Chromosome 17, 27423778: 27423779

Expression for Atypical Chronic Myeloid Leukemia

Search GEO for disease gene expression data for Atypical Chronic Myeloid Leukemia.

Pathways for Atypical Chronic Myeloid Leukemia

Pathways related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 ABL1 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
2
Show member pathways
13.23 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
3
Show member pathways
13.15 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
4
Show member pathways
13.11 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
5
Show member pathways
13.03 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
6
Show member pathways
12.8 FGFR1 JAK2 PDGFRA PDGFRB
7
Show member pathways
12.71 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
8
Show member pathways
12.62 FGFR1 JAK2 PDGFRA PDGFRB
9
Show member pathways
12.62 ABL1 FGFR1 PDGFRA PDGFRB
10
Show member pathways
12.48 ABL1 FGFR1 PDGFRA PDGFRB
11
Show member pathways
12.45 FGFR1 JAK2 PDGFRA PDGFRB
12 12.28 ABL1 PDGFRA PDGFRB
13
Show member pathways
12.27 FGFR1 PDGFRA PDGFRB
14
Show member pathways
12.21 FGFR1 PDGFRA PDGFRB
15 12.16 ABL1 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
16
Show member pathways
12.02 ABL1 FGFR1 PDGFRA PDGFRB
17
Show member pathways
11.92 ABL1 CSF3R JAK2 PDGFRA PDGFRB
18
Show member pathways
11.89 CSF3R FGFR1 PDGFRA PDGFRB
19 11.71 CSF3R FGFR1 PDGFRA PDGFRB
20 11.64 ABL1 CSF3R JAK2
21 11.62 FGFR1 PDGFRA PDGFRB
22 11.5 FGFR1 PDGFRA PDGFRB
23 11.45 FGFR1 PDGFRA PDGFRB
24 11.38 ABL1 PDGFRB
25 11.34 JAK2 PDGFRB
26 11.2 FGFR1 PDGFRA PDGFRB
27 11.19 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
28 11.13 FGFR1 PDGFRA PDGFRB
29 11.11 FGFR1 JAK2 PDGFRA PDGFRB
30 10.95 PDGFRA PDGFRB
31 10.69 PDGFRA PDGFRB

GO Terms for Atypical Chronic Myeloid Leukemia

Cellular components related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intrinsic component of plasma membrane GO:0031226 8.96 PDGFRA PDGFRB
2 receptor complex GO:0043235 8.92 CSF3R FGFR1 PDGFRA PDGFRB

Biological processes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.92 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
2 positive regulation of cell proliferation GO:0008284 9.91 FGFR1 JAK2 PDGFRA PDGFRB
3 protein phosphorylation GO:0006468 9.91 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
4 positive regulation of cell migration GO:0030335 9.8 JAK2 PDGFRA PDGFRB
5 cell migration GO:0016477 9.79 FGFR1 PDGFRA PDGFRB
6 positive regulation of protein kinase B signaling GO:0051897 9.78 FGFR1 PDGFRA PDGFRB
7 positive regulation of cytosolic calcium ion concentration GO:0007204 9.77 ABL1 JAK2 PDGFRA
8 MAPK cascade GO:0000165 9.76 FGFR1 JAK2 PDGFRA PDGFRB
9 positive regulation of MAPK cascade GO:0043410 9.73 FGFR1 PDGFRA PDGFRB
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.67 ABL1 PDGFRA PDGFRB
11 positive regulation of fibroblast proliferation GO:0048146 9.65 PDGFRA PDGFRB
12 response to retinoic acid GO:0032526 9.64 ASXL1 PDGFRB
13 thymus development GO:0048538 9.64 ABL1 ASXL1
14 skeletal system morphogenesis GO:0048705 9.63 FGFR1 PDGFRA
15 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.62 PDGFRA PDGFRB
16 cardiac myofibril assembly GO:0055003 9.6 PDGFRA PDGFRB
17 regulation of actin cytoskeleton reorganization GO:2000249 9.58 ABL1 PDGFRA
18 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.58 JAK2 PDGFRB
19 negative regulation of cell-cell adhesion GO:0022408 9.57 ABL1 JAK2
20 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.56 FGFR1 JAK2 PDGFRA PDGFRB
21 cell differentiation GO:0030154 9.55 ABL1 JAK2
22 peptidyl-tyrosine phosphorylation GO:0018108 9.55 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
23 retina vasculature development in camera-type eye GO:0061298 9.54 PDGFRA PDGFRB
24 phosphatidylinositol-mediated signaling GO:0048015 9.54 FGFR1 PDGFRA PDGFRB
25 positive regulation of phospholipase C activity GO:0010863 9.5 FGFR1 PDGFRA PDGFRB
26 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.48 ABL1 PDGFRB
27 metanephric glomerular capillary formation GO:0072277 9.43 PDGFRA PDGFRB
28 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.4 PDGFRA PDGFRB
29 protein autophosphorylation GO:0046777 9.35 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
30 platelet-derived growth factor receptor signaling pathway GO:0048008 8.92 ABL1 JAK2 PDGFRA PDGFRB

Molecular functions related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.89 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
2 kinase activity GO:0016301 9.72 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
3 nucleotide binding GO:0000166 9.71 FGFR1 JAK2 PDGFRA PDGFRB
4 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.51 ABL1 JAK2
5 SH2 domain binding GO:0042169 9.48 ABL1 JAK2
6 phosphatidylinositol 3-kinase binding GO:0043548 9.46 JAK2 PDGFRB
7 platelet-derived growth factor receptor binding GO:0005161 9.43 PDGFRA PDGFRB
8 platelet-derived growth factor binding GO:0048407 9.37 PDGFRA PDGFRB
9 protein kinase activity GO:0004672 9.35 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 FGFR1 PDGFRA PDGFRB
11 vascular endothelial growth factor binding GO:0038085 9.26 PDGFRA PDGFRB
12 protein tyrosine kinase activity GO:0004713 9.02 ABL1 FGFR1 JAK2 PDGFRA PDGFRB
13 protein binding GO:0005515 10.18 ABL1 ASXL1 CSF3R FGFR1 JAK2 PCM1

Sources for Atypical Chronic Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....